Market News / Story
Eli Lilly Stocks Jump 3.7% as $870 Million Protein Deal Expands
GuruFocus ·
GuruFocus reports: Eli Lilly , the medicines and metabolic-disease company, expanded its drug-discovery partnership with Gate Bioscience, with shares up approximately 3.6% at 11.44am EST to $1,200.23 on October 7, 2026. The target: proteins that have proved tough for conventional medicines to tackle. The valuation picture shows shares sitting 23.49% below the roughly $1,570 GF Value estimate, suggesting potential upside if the assumptions behind that estimate hold. The expanded agreement…